Butterfly needles Market Research Report and Outlook by 2028

The butterfly needles market is projected to expand from US$ 178,164 thousand in 2021 to US$ 309,647 thousand by 2028, reflecting a compound annual growth rate (CAGR) of 8.3% from 2022 to 2028.

The primary factors fueling the growth of the global butterfly needles market include the increasing incidence of chronic illnesses and the benefits that butterfly needles offer compared to traditional straight needles. Nonetheless, the potential for injuries related to butterfly needle sticks poses a challenge to market expansion.

Butterfly needles are specialized instruments utilized for blood collection or medication administration through veins. They are particularly beneficial for patients who present difficulties during venipuncture, such as the elderly, infants, and young children. Commonly referred to as winged infusion sets or scalp vein sets, these needles feature plastic wings on either side of the hollow needle, enhancing their usability. The design of butterfly needles, which includes flexible winged tubing, makes them easier to handle and less painful for patients. They are frequently employed in pediatric and geriatric care for blood draws and medication delivery.

Recent statistics from the World Health Organization indicate that cardiovascular diseases are responsible for the majority of deaths linked to non-communicable diseases, claiming approximately 17.9 million lives annually. This is followed by cancer, which accounts for around 10 million deaths, chronic respiratory diseases at 4.1 million, and diabetes at 2 million, including kidney-related fatalities. Cancer remains a leading global cause of death, with nearly 10 million fatalities in 2020, equating to about one in six deaths. Tumor marker tests, which analyze blood samples for cancer-specific chemicals, often utilize butterfly needles for blood collection and medication administration in oncology patients.

Additionally, butterfly needles are essential for blood draws related to cholesterol testing. Elevated cholesterol levels can lead to severe health issues such as heart attacks and strokes. The World Heart Federation reports that high cholesterol is responsible for approximately 4.4 million deaths each year, representing 7.8% of total deaths, with around 24% of cardiovascular-related fatalities linked to high LDL cholesterol levels.

The COVID-19 pandemic significantly disrupted daily life and business operations globally, with the pharmaceutical supply chain in the United States facing substantial challenges. The spread of the SARS-CoV-2 virus adversely affected various economic sectors, including healthcare. The pandemic placed immense strain on healthcare systems, impacting the operational capabilities of biopharmaceutical firms and clinical laboratories. Laboratories were under pressure to enhance testing capacities and expedite research and development efforts to provide timely clinical outcomes. The surge in COVID-19 cases negatively influenced the butterfly needles market in the United States, as visits from patients with cardiovascular conditions declined during the pandemic. In Europe, the pandemic led to business slowdowns or closures, affecting butterfly needle manufacturers. Although the demand for butterfly needles surged due to increased hospitalizations, production was hindered by workforce reductions aimed at curbing virus transmission. Furthermore, the pandemic disrupted the entire supply chain.

Blood supply, a critical resource for many patients, was one of the healthcare sectors most affected. Conditions such as trauma, renal failure, cancer, and sickle cell anemia require blood and blood products, including cryoprecipitate, plasma, immune globulins, and platelets. Many blood transfusion centers fell short of their collection targets during the pandemic. For instance, the Zambia National Blood Transfusion Services aimed to collect 18,750 units in the first quarter of 2020 but only managed to gather 6,516 units, or 34.7% of the goal. Blood donation campaigns also saw a decline; the Association of Friends of the National Cancer Institute (AFNCI) organized 150 campaigns in 2020, collecting 3,764 blood bags, compared to 288 campaigns and 7,838 bags in 2019. These factors collectively hindered the growth of the butterfly needles market. A report from the Organization for Economic Co-operation and Development (OECD) in November 2020 indicated that services for preventing and treating cardiovascular diseases, cancer, and diabetes were severely disrupted due to the pandemic. Additionally, the American College of Cardiology reported a 47% decline in diagnostic cardiovascular procedures in Asia in March 2020 compared to the previous year. The Asia Pacific region experienced a significant number of deaths among older adults during the COVID-19 crisis. Consequently, the butterfly needles market faced challenges during the pandemic due to lockdowns and restricted access to healthcare facilities. However, in the post-COVID landscape, there has been a notable increase in demand for butterfly needles, driven by the rising need for treatments related to cardiovascular diseases, cancer, and diabetes, which is expected to support future market growth.

Application-Based Insights

The butterfly needles market is segmented based on application into blood collection, IV rehydration, medication delivery, venipuncture, and blood transfusion. The blood collection segment dominated the market with a share of 34.3% in 2021.

End User-Based Insights

In terms of end users, the butterfly needles market is divided into hospitals, clinics, blood banks, and others. The hospital segment held the largest market share in 2021 and is anticipated to experience the highest CAGR of 9.1% during the forecast period.

Key sources referenced in the preparation of the butterfly needles market report include the World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine, among others.